Antigen binding molecules that bind EGFR, vectors encoding...

Details Antigen binding molecules that bind EGFR, vectors encoding... Antigen binding molecules that bind EGFR, vectors encoding...

2007-08-17

2010-12-07

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S141100, C424S142100, C424S143100, C424S178100

Reexamination Certificate

active

07846432

ABSTRACT:
The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225539 (1993-07-01), Winter
patent: 5558864 (1996-09-01), Bendig et al.
patent: 5891996 (1999-04-01), Mateo de Acosta del Rio et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6602684 (2003-08-01), Umaña et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6737056 (2004-05-01), Presta
patent: 6815184 (2004-11-01), Stomp et al.
patent: 7657380 (2010-02-01), Lazar et al.
patent: 7662377 (2010-02-01), Umana et al.
patent: 2001/0049105 (2001-12-01), Singh et al.
patent: 2002/0128448 (2002-09-01), Reff
patent: 2003/0039649 (2003-02-01), Foote
patent: 2003/0040606 (2003-02-01), Leung
patent: 2003/0115614 (2003-06-01), Kanda et al.
patent: 2003/0157108 (2003-08-01), Presta
patent: 2003/0175269 (2003-09-01), Black et al.
patent: 2003/0175884 (2003-09-01), Umaña et al.
patent: 2003/0190689 (2003-10-01), Crosby et al.
patent: 2004/0072290 (2004-04-01), Umaña et al.
patent: 2004/0093621 (2004-05-01), Shitara et al.
patent: 2004/0110282 (2004-06-01), Kanda et al.
patent: 2004/0110704 (2004-06-01), Yamane et al.
patent: 2004/0132066 (2004-07-01), Balint et al.
patent: 2004/0132097 (2004-07-01), Bacus et al.
patent: 2004/0132101 (2004-07-01), Lazar et al.
patent: 2004/0132140 (2004-07-01), Satoh et al.
patent: 2004/0241817 (2004-12-01), Umaña et al.
patent: 2005/0074843 (2005-04-01), Umaña et al.
patent: 2005/0079605 (2005-04-01), Umaña et al.
patent: 2005/0123546 (2005-06-01), Umaña et al.
patent: 2005/0142133 (2005-06-01), Lazar et al.
patent: 2005/0272128 (2005-12-01), Umaña et al.
patent: 2006/0269545 (2006-11-01), Umana et al.
patent: 2008/0095770 (2008-04-01), Umana et al.
patent: 2008/0286277 (2008-11-01), Umana et al.
patent: 2009/0186019 (2009-07-01), Umana et al.
patent: 2010/0081796 (2010-04-01), Brinkmann et al.
patent: 1 176 195 (2002-01-01), None
patent: WO 95/20045 (1995-07-01), None
patent: WO 99/54342 (1999-10-01), None
patent: WO 03/056914 (2003-07-01), None
patent: WO 03/078614 (2003-09-01), None
patent: WO 03/084570 (2003-10-01), None
patent: WO 03/085119 (2003-10-01), None
patent: WO 2004/024927 (2004-03-01), None
patent: WO 2004/057002 (2004-07-01), None
patent: WO 2004/063351 (2004-07-01), None
patent: WO 2004/065540 (2004-08-01), None
patent: WO 2004/099249 (2004-11-01), None
patent: WO 2005/056606 (2005-06-01), None
patent: WO 2005/056759 (2005-06-01), None
patent: WO 2007/031875 (2007-03-01), None
Roitt et al, p. 5.8 and 5.9, in Immunology second edition, Gower Medical Publishing New York 1989.
Brown et al, J Immunol 156(9): 3285-91, May 1996.
Vajdos et al, J Mol Biol 320(2): 415-428, Jul. 5, 2002.
Caldas et al, Mol. Immunol. 39 (15): 941-952, May 2003.
Davies, J., et al., “Expression of GnTIII in a Recombinant Anti-CD20 CHO Production Cell Line: Expression of Antibodies with Altered Glycoforms Leads to an Increase in ADCC Through Higher Affinity for FcγRIII,”Biotechnol. Bioeng.74:288-294, John Wiley & Sons, Inc. (2001).
Shields, R.L., et al., “Lack of Fucose on Human IgG1N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity,”J. Biol. Chem.277:26733-26740, The American Society for Biochemistry and Molecular Biology, Inc. (2002).
Arteaga, C.L. and Baselga, J., “Clinical Trial Design and End Points for Epidermal Growth Factor Receptor-targeted Therapies: Implications for Drug Development and Practice,”Clin. Cancer Res.9:1579-1589, The American Association for Cancer Research (2003).
Bleeker, W.K., et al., “Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy,”J. Immunol.173:4699-4707, The American Association of Immunologists, Inc. (2004).
Modjtahedi, H., et al., “Antitumor Activity of Combinations of Antibodies Directed Against Different Epitopes on the Extracellular Domain of the Human EGF Receptor,”Cell Biophysics22:129-146, Humana Press Inc. (1993).
Sumitomo, M., et al., “ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase Pathway,”Clin. Cancer Res.10:794-801, The American Association for Cancer Research (2004).
Bianco, R., et al., “Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor,”Current Drug Targets6:275-287, Bentham Science Publishers Ltd (May 2005).
Barrios, Y., et al., “Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor,”J. Mol. Recognit.17:332-338, John Wiley & Sons, Ltd. (2004).
Kobrin, B.J., et al., “A V Region Mutation in a Phosphocholine-Binding Monoclonal Antibody Results in Loss of Antigen Binding,”Journal of Immunology146:2017-2020, The American Association of Immunologists (1991).
Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding specificity,”Proc. Natl. Acad. Sci.USA 79:1979-1983, National Academy of Sciences (1982).
Shields, R.L., et al., “Lack of Fucose on Human IgG1N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependant Cellular Toxicity,”J. of Biol. Chem.277:26733-26740, The American Society for Biochemistry and Molecular Biology, Inc. (2002).
Andersen, D.C. and Krummen, L., “Recombinant protein expression for therapeutic applications,”Curr. Opin. Biotechnol.13:117-123, Elsevier Science Ltd. (2002).
Appelbaum, F.R., “Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma,”Hematol./Oncol. Clin. N. Am.5:1013-1025, W.B. Saunders (1991).
Atalay, G., et al., “Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer,”Ann. Oncol.14:1346-1363, Oxford University Press (2003).
Becker, J., “Signal transduction inhibitors—a work in progress,”Nat. Biotechnol.22:15-18, Nature America Publishing (Jan. 2004).
Bier, H., et al., “Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma,”Eur. Arch. Otorhinolaryngol.252:433-439, Springer-Verlag (1995).
Borth, N., et al., “Efficient Selection of High-Producing Subclones During Gene Amplification of Recombinant Chinese Hamster Ovary Cells by Flow Cytometry and Cell Sorting,”Biotechnol. Bioeng.71:266-273, John Wiley & Sons, Inc. (2001).
Boulianne, G.L., et al., “Production of functional chimaeric mouse/human antibody,”Nature312:643-646, Macmillan Journals Ltd. (1984).
Bowie, J.U., et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science247:1306-1310, American Association for the Advancement of Science (1990).
Carter, P., et al., “Humanization of an anti-p185HER2antibody for human cancer therapy,”Proc. Natl. Acad. Sci.USA 89:4285-4289, National Academy of Sciences (1992).
Cartron, G., et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene,”Blood99:754-758, America

Affiliated with

Also associated with

Rating

Antigen binding molecules that bind EGFR, vectors encoding... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antigen binding molecules that bind EGFR, vectors encoding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen binding molecules that bind EGFR, vectors encoding... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4156626